Fluticasone with vilanterol

For the prophylaxis of asthma.
• Over 12 years: 160 micrograms once daily; reduced to 80 micrograms once daily, if control maintained; increased if necessary up to 320 micrograms twice daily, in severe asthma.

Budelin Novoliser for prophylaxis of asthma by inhalation of powder
• Adult: 200–800 mcg twice daily
Budelin Novoliser as an alternative in mild to moderate asthma by inhalation of powder, for patients previously stabilised on a twice-daily dose
• Adult: 200–400 mcg once daily to be taken in the evening. Maximum per dose 800 mcg.

For allergic rhinitis
• Over 12 years: one spray twice daily, dose to be administered into each nostril.

For the treatment of anaphylaxis and asthma.

By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.

By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.

By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.

For the treatment of anaphylaxis and asthma.

By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.

By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.

By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.

By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.

By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.

By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.

By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.

By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.

By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.

By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner. 

For allergic rhinitis
• Over 12 years: one spray twice daily, dose to be administered into each nostril.

For the prophylaxis of asthma by inhalation of powder
• Child 5–15 years: initially 50–100 mcg twice daily (maximum per dose 200 mcg twice daily), dose to be adjusted as required.
• Over 16 years: initially 100–500 mcg twice daily (maximum per dose 1 mg twice daily). Dose may be increased according to severity of asthma. Doses above 500 mcg twice daily initiated by a specialist.

For the prophylaxis of asthma by inhalation of aerosol
• Child 4–15 years: initially 50–100 mcg twice daily (maximum per dose 200 mcg twice daily), dose to be adjusted as required.
• Over 16 years: initially 100–500 mcg twice daily (maximum per dose 1 mg twice daily). Dose may be increased according to severity of asthma. Doses above 500 mcg twice daily initiated by a specialist.

For the prophylaxis of asthma by inhalation of nebulised suspension
• Child 4–15 years: 1 mg twice daily.
• Over 16 years: 0.5–2 mg twice daily.

Prophylaxis treatment of allergic and perennial rhinitis by nasal spray
• Child 4–11 years: 50 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 50 mcg twice daily.
• Over 12 years: 100 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 100 mcg twice daily. Reduce to 50 mcg once daily when controlled.
Prophylaxis treatment of nasal polyps by nasal spray
• Over 16 years: 200 mcg one to two times per
day administered into each nostril. If no improvement in four to six weeks, consider alternative treatment.

For nasal polyps using nasal drops
Over 16 years: 200 mcg 1–2 times a day, to be administered into each nostril, alternative treatment should be considered if no improvement after 4–6 weeks, (200 mcg is equivalent to approximately 6 drops).

Long-acting selective beta2 agonist with corticosteroid.

Combisal 25/125
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Combisal 25/50
• Over 4 years for prophylaxis of asthma: two inhalations twice daily, but can be reduced to two inhalations once daily.
Combisal 25/250
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.

Long-acting selective beta2 agonist with corticosteroid.

Sereflo Ciphaler 50/250 for prophylaxis of asthma
• Over 12 years: 1 inhalation twice daily, reduced to 1 inhalation once daily, use reduced dose only if control maintained.
Sereflo 125 for moderate to serve asthma
• Adult: 2 inhalations twice daily.
Sereflo 250 for moderate to severe asthma
• Adult: 2 inhalations twice daily.

Long-acting selective beta2 agonist with corticosteroid.

Stalpex 500/50 mcg
• For symptomatic treatment of COPD with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
• Adult: one inhalation twice daily.

Stalpex is indicated for use in patients with severe asthma 12 years of age and older only, where patients not adequately controlled on a lower strength corticosteroid combination product; or patients already adequately controlled on an inhaled corticosteroid in a high strength and a long-acting beta2 agonist.
• Adults and adolescents 12 years and older: One inhalation, twice daily

Long acting muscarinic antagonist, long-acting beta 2 agonist and inhaled corticosteroid. Two inhalations twice daily